AI will “turbocharge” medical billing and drive up costs in the short term, CMS Administrator Dr. Mehmet Oz warned Wednesday. But he said the pain is worth it for long-term savings.
AI will inflate healthcare costs before lowering them, Oz says Read More »
AI will “turbocharge” medical billing and drive up costs in the short term, CMS Administrator Dr. Mehmet Oz warned Wednesday. But he says the pain is worth it for long-term savings.
AI will inflate healthcare costs before lowering them, Oz says Read More »
Jodee Kozlak, a veteran of major multinational corporations, will join UnitedHealth this coming Monday to modernize and align the healthcare behemoth’s operations across its various businesses.
UnitedHealth names first chief administrative officer Read More »
Índice La desconfianza, en cifras ¿Por qué desconfiamos exactamente? Qué ocurre cuando se automatiza esa comparación El efecto medible de comparar en lugar de confiar Lo que esto significa para quien usa IA para traducir Pedirle u …
While Acadia Pharmaceuticals’ candidate has missed the main goal of a Phase 2 trial, the company is still moving forward with the anti-psychosis candidate in Alzheimer’s disease as well as Lewy body dementia.
Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward Read More »
The weekly insulin Onswik will now be available to U.S. patients after initial approvals in Europe, Mexico and Japan.
Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry Read More »
Kyverna Therapeutics’ miv-cel showed improved mobility and a favorable safety profile at one year in patients with stiff person syndrome, further derisking an upcoming FDA application, William Blair said on Thursday. The biotech plans to file for priority review this year.
Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data Read More »
Analysts were keen to see a new modality compete with Roche’s approved drug Lucentis in the late-stage trial but new safety issues could complicate the future for Merck’s candidate.
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge Read More »
InnoCare Pharma is the latest addition to Eli Lilly’s dealmaking spree, which includes some of the biggest acquisitions this year: up to $7 billion for Kelonia Therapeutics in April and up to $7.8 billion for Centessa Pharmaceuticals in March.
Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare Read More »
The new partnership follows Roche’s recent R&D expansion in Boston focused on development for cardiovascular, renal and metabolic diseases.
Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs Read More »
